1. State of the Art in HCC: Immune Checkpoint Modulation

2. Hepatocellular Carcinoma Background

3. Immune Checkpoint Modulation in HCC

4. Standard of Care for HCC First-Line and Second-Line Treatments

5. Investigational Agents Lenvatinib in HCC

6. Tremelimumab: Phase 2 Study in HCV Associated HCC Cohort

7. Tremelimumab: Phase 2 Study Results

8. Checkpoint Inhibitors: PD-1/PD-L1

9. Nivolumab Phase 1/2 Dose-Escalation and Expansion: CheckMate 040 Study

10. CheckMate 040: Phase 1 and 2 Overall Results

11. CheckMate 040: Phase 1 and 2 Individual Results

12. KEYNOTE-224: Pembrolizumab in Previously Treated Advanced HCC

13. KEYNOTE-240: Pembrolizumab vs BSC for Second-Line Advanced HCC

14. Phase 1 Durvalumab in Multiple Solid Tumor Types

15. Phase 1/2: Durvalumab and Tremelimumab as Monotherapy and in Combination with Unresectable HCC

16. Atezolizumab Plus Bevacizumab in Solid Tumors

17. CheckMate 459 Nivolumab vs Sorafenib

18. CheckMate-040 Safety Data

19. AE Management Issues

20. Predictive Biomarkers for Response to Immunotherapy

21. Concluding Remarks

22. Abbreviations

23. Abbreviations (cont)

24. Abbreviations (cont)